Derrington brings a wealth of international operational and industry leadership, experience, and specific knowledge for maximizing operational performance, business development, and strategic partnerships.

Recently, Derrington was chairman and CEO of Axient Research, a CRO developing clinical research solutions to deliver reliable and accurate patient data to accelerate the development of safe and effective drug and medical treatments.

Prior to Axient, Derrington was the CEO of BioReliance Corp (Invitrogen Corp), a research company providing biologic testing and manufacturing and toxicology services to global companies that span the product cycle from early preclinical development to licensed production.

Over the duration of his career, he has held management positions with Quintiles Transnational Corp (senior vice president of Corporate Development); Quintiles Laboratories Worldwide (COO); Mayo Clinic (administrative director of Clinical Trials); and Shell UK Ventures (MD and project manager).

MPI Research chairman and CEO William Parfet said as president and COO Tim Derrington will help them scale their operations and expand their presence globally.

"He represents the depth that is essential to our top management team, and his knowledge, leadership ability, and industry experience will be among our most valuable assets," Parfet said.